AUPH Q1 2024 Earnings — Aurinia Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

AUPHAurinia Pharmaceuticals Inc.

$2B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$50M+46.2% YoY

Gross Profit

$43M84.6% margin

Operating Income

-$11M-21.3% margin

Net Income

-$11M-21.4% margin

EPS (Diluted)

$-0.07

QoQ Revenue Growth

+11.5%

Cash Flow

Operating Cash Flow

-$19M

Free Cash Flow

-$19M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$517M

Total Liabilities

$157M

Stockholders' Equity

$359M

Cash & Equivalents

$64M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$50M	$34M	+46.2%
Gross Profit	$43M	$34M	+25.2%
Operating Income	-$11M	-$30M	+63.8%
Net Income	-$11M	-$26M	+59.0%

Revenue Segments

Product

$48M96%

License, Royalty and Collaboration Revenue

$2M4%